ArticleBasic & clinical pharmacology & toxicology2025
Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co-Design Approach With General Practitioners and Patients.
Article in Basic & clinical pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis.Cancer reports (Hoboken, N.J.) · 2026Review
- Identifying deprescribing profiles in older adults from 14 countries using the Patient Deprescribing Typology.Innovation in aging · 2026Article
- Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co-Design Approach With General Practitioners and Patients.Basic & clinical pharmacology & toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Proton Pump Inhibitors (PPIs) are widely prescribed medications globally. PPIs are often inappropriately used - for example, prescribed without a clear indication, at higher-than-necessary doses, or for longer durations than needed - resulting in increased risks of adverse health outcomes such as nutrient deficiencies, osteoporosis-related fractures, and kidney disease. The effectiveness of current deprescribing interventions is inconsistent; this may relate to the misalignment with behavioural mechanisms, supporting the need for a mechanism-driven approach that targets key behavioural determinants. We co-designed a PPI deprescribing intervention with patients and health professionals for the Swiss primary care setting. This involved identifying behavioural determinants of PPI deprescribing from the literature at both the general practitioner (GP) and patient levels, mapping them to behaviour change techniques, selecting intervention elements, and developing contextualised intervention tools to effectively influence these determinants. The intervention tools were iteratively developed and assessed through qualitative methods with 16 patients and 18 health professionals. Participants considered the tools to be acceptable and practical for use in the Swiss primary care context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.